Literature DB >> 32029053

Burden of Cirrhosis and Other Chronic Liver Diseases Caused by Specific Etiologies in China, 1990-2016: Findings from the Global Burden of Disease Study 2016.

Man Li1, Zhuo Qun Wang2, Lu Zhang1, Hao Zheng3, Dian Wu Liu1, Mai Geng Zhou2.   

Abstract

OBJECTIVE: To estimate the burden of cirrhosis and other chronic liver diseases caused by specific etiologies in China.
METHODS: Data from the Global Burden of Disease Study 2016 (GBD 2016) were used. We evaluated the burden by analyzing age-sex-province-specific prevalence, mortality, and disability-adjusted life-years (DALYs) of 33 provinces in China.
RESULTS: From 1990 to 2016, prevalence cases in thousands increased by 73.7% from 6833.3 (95% UI: 6498.0-7180.6) to 11869.6 (95% UI: 11274.6-12504.7). Age-standardized mortality and DALY rates per 100,000 decreased by 51.2% and 53.3%, respectively. Male and elderly people (aged ≥ 60 years) preponderance were found for prevalence, mortality, and DALYs. The number of prevalence cases, deaths, and DALYs due to hepatitis C virus (HCV) increased by 86.6%, 8.7%, and 0.9%, respectively. Also, age-standardized prevalence rates decreased in 31 provinces, but increased in Yunnan and Shandong. The Socio-demographic Index (SDI) values were negatively correlated with age-standardized mortality and DALY rates by provinces in 2016; the correlation coefficients were -0.817 and -0.828, respectively.
CONCLUSION: Cirrhosis and other chronic liver diseases remain a huge health burden in China, with the increase of population and the aging of population. Hepatitis B virus (HBV) remains the leading cause of the health burden in China.
Copyright © 2020 The Editorial Board of Biomedical and Environmental Sciences. Published by China CDC. All rights reserved.

Entities:  

Keywords:  China; Chronic liver disease; Cirrhosis; Epidemiology; Global burden of disease study

Mesh:

Year:  2020        PMID: 32029053     DOI: 10.3967/bes2020.001

Source DB:  PubMed          Journal:  Biomed Environ Sci        ISSN: 0895-3988            Impact factor:   3.118


  3 in total

1.  Lusutrombopag for thrombocytopenia in Chinese patients with chronic liver disease undergoing invasive procedures.

Authors:  Zhenbin Ding; Hong Wu; Yongyi Zeng; Ming Kuang; Wei Yang; Zhiqiang Meng; Yajin Chen; Chunyi Hao; Shubing Zou; Huichuan Sun; Chang Liu; Kecan Lin; Guoming Shi; Xiaoying Wang; Xiutao Fu; Rongxin Chen; Yi Chen; Ruifang Liang; Takeshi Kano; Huiyan Pan; Suna Yang; Jia Fan; Jian Zhou
Journal:  Hepatol Int       Date:  2022-10-18       Impact factor: 9.029

Review 2.  Definition and classification of acute-on-chronic liver diseases.

Authors:  Yuan-Yao Zhang; Zhong-Ji Meng
Journal:  World J Clin Cases       Date:  2022-05-26       Impact factor: 1.534

3.  Sarcopenia as a prognostic predictor of liver cirrhosis: a multicentre study in China.

Authors:  Xin Zeng; Zhi-Wen Shi; Jia-Jun Yu; Li-Fen Wang; Yuan-Yuan Luo; Si-Min Jin; Li-Yuan Zhang; Wei Tan; Pei-Mei Shi; Hong Yu; Chun-Qing Zhang; Wei-Fen Xie
Journal:  J Cachexia Sarcopenia Muscle       Date:  2021-09-14       Impact factor: 12.910

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.